Holzer & Holzer Reminds Investors of Lead Plaintiff Deadlines in Shareholder Lawsuits

Law firm alerts investors to upcoming deadlines to seek lead plaintiff status in class action suits against Aquestive Therapeutics, Nektar Therapeutics, and Eos Energy Enterprises.

Apr. 6, 2026 at 11:08pm

Got story updates? Submit your updates here. ›

A minimalist, high-contrast studio photograph featuring a stack of legal documents, a wooden gavel, and a pair of reading glasses arranged on a plain white background, symbolizing the serious nature of corporate litigation and shareholder rights.This conceptual still life captures the gravity of shareholder lawsuits seeking to hold public companies accountable for alleged misconduct.Atlanta Today

The law firm Holzer & Holzer, LLC is reminding investors of the deadlines to seek lead plaintiff status in shareholder class action lawsuits against Aquestive Therapeutics, Nektar Therapeutics, and Eos Energy Enterprises. The lawsuits allege the companies made false or misleading statements regarding their drug trials and production capabilities, causing significant investor losses.

Why it matters

These shareholder class action lawsuits are part of a broader trend of increased securities litigation, as investors seek to hold public companies accountable for alleged corporate misconduct that impacts stock prices. The deadlines to join these specific cases as a lead plaintiff are fast approaching, so affected investors are being urged to act quickly to protect their legal rights.

The details

The lawsuits allege the following: Aquestive Therapeutics is accused of making false or misleading statements about its New Drug Application for the drug Anaphylm; Nektar Therapeutics is accused of making false or misleading statements about its REZOLVE-AA trial; and Eos Energy Enterprises is accused of making false or misleading statements about its ability to ramp up production and capacity utilization. Investors who purchased shares in these companies during the specified time periods and suffered significant losses are encouraged to contact Holzer & Holzer to discuss joining the lawsuits as lead plaintiffs.

  • The deadline to seek lead plaintiff status in the Aquestive Therapeutics case is May 4, 2026.
  • The deadline to seek lead plaintiff status in the Nektar Therapeutics case is May 5, 2026.
  • The deadline to seek lead plaintiff status in the Eos Energy Enterprises case is May 5, 2026.

The players

Holzer & Holzer, LLC

A securities litigation law firm that is representing investors in these shareholder class action lawsuits. The firm has been top-rated by ISS for securities litigation in 2021, 2022, 2023, and 2025.

Aquestive Therapeutics, Inc.

A pharmaceutical company accused of making false or misleading statements about its New Drug Application for the drug Anaphylm.

Nektar Therapeutics

A biopharmaceutical company accused of making false or misleading statements about its REZOLVE-AA trial.

Eos Energy Enterprises, Inc.

An energy storage company accused of making false or misleading statements about its ability to ramp up production and capacity utilization.

Corey D. Holzer

An attorney at Holzer & Holzer, LLC who is responsible for the content of this communication and who investors can contact to discuss their legal rights.

Got photos? Submit your photos here. ›

What they’re saying

“If you purchased Aquestive shares during this time period and suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm's website at www.holzerlaw.com/case/aquestive-therapeutics/ to learn more.”

— Corey D. Holzer, Attorney, Holzer & Holzer, LLC

“If you purchased Nektar shares during this time period and suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm's website at www.holzerlaw.com/case/nektar-therapeutics/ to learn more.”

— Corey D. Holzer, Attorney, Holzer & Holzer, LLC

“If you purchased Eos Energy shares during this time period and suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm's website at www.holzerlaw.com/case/eos-energy-enterprises/ to learn more.”

— Corey D. Holzer, Attorney, Holzer & Holzer, LLC

What’s next

Investors have until the specified deadlines to ask the court to be appointed lead plaintiff in the respective class action lawsuits against Aquestive Therapeutics, Nektar Therapeutics, and Eos Energy Enterprises.

The takeaway

These shareholder lawsuits highlight the growing trend of investors seeking to hold public companies accountable for alleged corporate misconduct that impacts stock prices. Affected investors are encouraged to act quickly to protect their legal rights by contacting Holzer & Holzer before the fast-approaching lead plaintiff deadlines.